Meiragtx Holdings PLC

MeiraGTx Holdings plc announced a significant strategic investment of up to $400 million from Oberland Capital, comprising $375 million in non-dilutive capital and $25 million in equity, to advance its late-stage gene therapy programs.

MeiraGTx Holdings plc announces results from its annual general meeting, with directors elected and auditor ratified.

MeiraGTx announced first quarter 2026 financial and operational results, highlighted by the acquisition of bota-vec for XLRP and positive three-year data for AAV2-hAQP1, alongside a $100 million financing.

MeiraGTx Holdings plc has completed the initial closing of a strategic collaboration with Hologen Limited to advance gene therapies for Parkinson's disease and obesity, along with a proprietary delivery device.

MeiraGTx Holdings plc has entered into an underwriting agreement to issue 11,111,111 ordinary shares at $9.00 per share to raise approximately $93.3 million in net proceeds.

MeiraGTx has reacquired the rights to its gene therapy product, bota-vec, from Janssen Pharmaceuticals for $25 million upfront.

MeiraGTx Holdings plc filed its Q1 2026 Form 10-Q, detailing a net loss of $46.3 million and strategic advancements in its gene therapy pipeline, including the reacquisition of bota-vec.

MeiraGTx reports continued net losses in Q3 2025 but strengthens its financial position with significant upfront payments from new strategic collaborations with Eli Lilly and Hologen.

MeiraGTx reports increased Q2 losses but highlights a significant strategic collaboration with Hologen, securing substantial funding and advancing multiple gene therapy programs towards commercialization.

MeiraGTx Holdings plc announces its Q1 2025 financial results, emphasizing a strategic collaboration with Hologen, clinical advancements in AAV-GAD for Parkinson's disease, and progress in other gene therapy programs.

MeiraGTx Holdings reports a net loss of $39.3 million for the third quarter of 2024, with service revenue of $10.9 million and ongoing clinical development programs.

MeiraGTx Holdings reports a net loss of $69.1 million for the first six months of 2024, while highlighting progress in clinical trials and strategic collaborations.

MeiraGTx reported $81.4M in 2025 revenue driven by a $75M Lilly upfront, narrowed its net loss to $114.2M, secured FDA Breakthrough for its xerostomia gene therapy, and extended liquidity into H2 2027 pending a $200M Hologen collaboration closing in Q2 2026.

MeiraGTx Holdings PLC reports its financial results for the year ended December 31, 2024, highlighting progress in clinical programs and strategic collaborations.

Janssen Pharmaceuticals acquires MeiraGTx's RPGR program for up to $415 million, including an upfront payment and potential milestone payments.

Richard Giroux, CFO & COO of MeiraGTx Holdings plc, sold 56,000 shares of common stock on July 21, 2026 for $12.51 per share.

MeiraGTx Holdings plc reports that Chief Scientific Officer, Stuart Naylor, sold a significant number of ordinary shares under a pre-arranged trading plan.

MeiraGTx Holdings plc reports that Chief Medical Officer Robert K. Zeldin was granted 100,000 restricted share units.

MeiraGTx Holdings plc reports that General Counsel and Secretary Robert J. Wollin acquired 100,000 restricted share units.

MeiraGTx Holdings plc reports that Chief Scientific Officer, Stuart Naylor, was granted 70,000 restricted share units on June 25, 2026.

MeiraGTx Holdings plc reports that CFO & COO Richard Giroux was granted 980,000 restricted share units on June 25, 2026, with vesting over four years.

MeiraGTx Holdings plc announces its 2026 Annual General Meeting of Shareholders, scheduled for June 11, 2026, to elect directors and ratify auditor appointment.

MeiraGTx Holdings plc will hold its Annual General Meeting virtually on June 12, 2025, and shareholders are encouraged to vote on key proposals.

MeiraGTx Holdings plc announces its 2025 annual general meeting of shareholders to be held on June 12, 2025, featuring director election and auditor ratification proposals.

MeiraGTx Holdings plc has scheduled its 2024 Annual Meeting for June 6, 2024, and is providing proxy materials to shareholders for voting on key proposals.

MeiraGTx Holdings plc will hold its 2024 annual general meeting of shareholders on June 6, 2024, to vote on director elections, executive compensation, and the ratification of the company's independent auditor.

Perceptive Advisors LLC reported an increased beneficial ownership of 12.6% in MeiraGTx Holdings plc following a recent share purchase.

MeiraGTx Holdings plc executed an $18.19 million share repurchase from Perceptive Life Sciences Master Fund, reducing Perceptive's stake to 12.9%.

Adage Capital Management, L.P. has reported beneficial ownership of 4,000,000 ordinary shares in MeiraGTx Holdings plc, representing 4.91% of the class.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 5.20% beneficial ownership stake in MeiraGTx Holdings plc, totaling 4,184,578 ordinary shares.

Prosight Management, LP and its affiliates have filed an amended Schedule 13G, reporting a collective beneficial ownership of 5.4% of MeiraGTx Holdings plc's Ordinary Shares as of March 31, 2025.